Figure 6.

Inhibition of tumor growth by HSA-PEG/PTX in an animal tumor model. (a) Inhibition of SK-BR-3 tumor growth by HSA-PEG/PTX. One hundred microliters of the desired formulations were systemically administered to tumor-bearing mice on days 0, 3, 5, 7, and 9. Tumor growth was monitored by measuring tumor volume as described in the Materials and methods section and expressed as a percent of the initial volume (100 mm²). The dose of PTX was 4 mg/kg. The results are presented as mean ± SD (n = 8/group). *p < .01 versus controls. (b) Mouse survival rate after the systemic administration of PTX, Abraxane^®, and HSA-PEG/PTX.